



PATENT

Attorney Docket No.: 33846/US/2/TAL/MWR/THR

Attorney File No.: 454892-00018

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SEMPLE et al.

Serial No. 10/086,477

Filing Date: March 1, 2002

For: *Compositions for Stimulating
Cytokine Secretion and Inducing an
Immune Response*

Examiner: Dave T. Nguyen

Art Unit: 1632

"EXPRESS MAIL" LABEL NO.:
EV 695792697 US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1287 Off. Gaz. Pat. Office 163, 10/19/2004, no copies of U.S. patents and U.S. published applications are enclosed. Copies of all other references are enclosed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application.

Serial No. 10/086,477

Filing Date: March 1, 2002

Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required.

While no further fee is believed to be due, if this belief is in error, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 454892-00036; Our Docket No. 33846/US/3).

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: _____

6/30/06

By: _____

Todd A. Lorenz, Reg. No. 39,754

Customer Number: 32940

Dorsey & Whitney LLP

Intellectual Property Department

Four Embarcadero Center, Suite 3400

San Francisco, CA 94111-4187

Telephone: (415) 781-1989

Facsimile: (415) 398-3249

Attachments : Form PTO/SB/8A, Substitute for form 1449

5 cited references

Return Postcard



Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/086,477
				Filing Date	March 1, 2002
				First Named Inventor	SEMPLE, Sean C.
				Art Unit	1632
				Examiner Name	Dave T. Nguyen
Sheet	1	of	1	Attorney Docket Number	33846/US/2 (454892-00018)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	B1					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	CHU, W.M., et al. "DNA-PKcs Is Required for Activation of Innate Immunity By Immunostimulatory DNA," <i>Cell</i> , Dec. 2002, 103, 909-918.	
	C2	DOW, S.W., et al., "Lipid-DNA complexes Induce Potent Activation of Innate Immune Responses and Antitumor Activity When Administered Intravenously," <i>Journal of Immunology</i> , 1999, 163, 1552-1561.	
	C3	HEMMI, H., et al., "A Toll-like receptor Recognizes Bacterial DNA," <i>Nature</i> , 2000, 408, 740-745.	
	C4	HOPE, M., et al., "Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs," <i>Mol. Membr. Biol.</i> 15(1):1-14 (Jan. - Mar. 1998).	
	C5	LATZ, E., et al., "TLR9 Signals After Translocating From the ER to CpG DNA in Lysosome," <i>Nature Immunology</i> , 2004, 5, 2, 190-198.	
	C6	ZELPHATI, O., et al., "Cationic Liposomes As An Oligonucleotide Carrier: mechanism of Action" <i>J. Liposome Research</i> , 1997, 7(1), 31-49.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2